Production of monoclonal antibodies for therapeutic purposes: A review

International Immunopharmacology, Journal Year: 2023, Volume and Issue: 120, P. 110376 - 110376

Published: May 25, 2023

Language: Английский

---

Bioengineering of Antibody Fragments: Challenges and Opportunities

Bioengineering, Journal Year: 2023, Volume and Issue: 10(2), P. 122 - 122

Published: Jan. 17, 2023

Antibody fragments are used in the clinic as important therapeutic proteins for treatment of indications where better tissue penetration and less immunogenic molecules needed. Several expression platforms have been employed production these recombinant proteins, from which E. coli CHO cell-based systems emerged most promising hosts higher expression. Because antibody such Fabs scFvs smaller than traditional structures do not require specific patterns glycosylation decoration efficacy, it is possible to express them with reduced post-translational modification capacity high yield, example, plant insect systems. In this review, we describe different bioengineering technologies along their opportunities difficulties manufacture consideration stability, efficacy safety humans. There still potential a new technology view being simple, fast cost-effective while maintaining stability biotherapeutic fragments.

Language: Английский

---

Rapid identification of A29L antibodies based on mRNA immunization and high-throughput single B cell sequencing to detect Monkeypox virus

Emerging Microbes & Infections, Journal Year: 2024, Volume and Issue: 13(1)

Published: March 22, 2024

With the large number of atypical cases in mpox outbreak, which was classified as a global health emergency by World Health Organization (WHO) on 23 July 2022, rapid diagnosis and diseases with similar symptoms to such chickenpox respiratory infectious early stages viral infection is key controlling spread outbreak. In this study, antibodies against monkeypox virus A29L protein were efficiently rapidly identified combining mRNA immunization high-throughput sequencing individual B cells. We obtained eight high affinity for validated ELISA, used basis developing an ultrasensitive fluorescent immunochromatographic assay based multilayer quantum dot nanobeads (SiTQD-ICA). The SiTQD-ICA biosensor utilizing M53 M78 showed sensitivity stability detection: detected within 20 min, minimum detection limit 5 pg/mL. A specificity test that method non-cross-reactive or common pathogens can be antigen detection. This antibody identification also acquisition monoclonal outbreaks other various studies.

Language: Английский

---

Whole-canine neutralizing antibodies generated by single B cell antibody technology elicit therapeutic protection against canine distemper virus infection

Veterinary Microbiology, Journal Year: 2025, Volume and Issue: unknown, P. 110412 - 110412

Published: Jan. 1, 2025

Language: Английский

---

Why recombinant antibodies — benefits and applications

Current Opinion in Biotechnology, Journal Year: 2019, Volume and Issue: 60, P. 153 - 158

Published: March 5, 2019

Language: Английский

---

Current status of immunotherapy for non-small cell lung cancer

Frontiers in Pharmacology, Journal Year: 2022, Volume and Issue: 13

Published: Oct. 13, 2022

Nowadays, lung cancer is still the deadliest oncological disease in world. Among them, non-small cell (NSCLC) accounts for 80%∼85% of all cancers, and its 5-year survival rate less than 15%, making situation critical. In past decades, despite some clinical advances conventional treatments, overall NSCLC not optimistic due to unique physiological conditions frequent occurrence tumor escape. recent years, immunotherapy has become a new hot spot research, including antibody therapy therapy, which have been developed utilized one after another, especially immune checkpoint inhibitor (ICI). These approaches effectively improved objective response patients by enhancing capacity body targeting cells more effectively, specific toxic compared with chemotherapy, providing strategies treatment. this paper, we reviewed relevant targets, progress adverse reaction monoclonal antibodies, antibody-drug conjugates, ICI, bispecific T-cell receptor engineered T (TCR-T), Chimeric antigen (CAR-T), also report on their combination from immune-related background provide better treatment prospective.

Language: Английский

---

Monoclonal antibodies in breast cancer: A critical appraisal

Critical Reviews in Oncology/Hematology, Journal Year: 2023, Volume and Issue: 183, P. 103915 - 103915

Published: Jan. 23, 2023

Language: Английский

---

SARS-Cov-2 Spike-S1 Antigen Test Strip with High Sensitivity Endowed by High-Affinity Antibodies and Brightly Fluorescent QDs/Silica Nanospheres

ACS Applied Materials & Interfaces, Journal Year: 2023, Volume and Issue: 15(23), P. 27612 - 27623

Published: June 2, 2023

The extensive research into developing novel strategies for detecting respiratory syndrome coronavirus 2 (SARS-CoV-2) antigens in clinical specimens, especially the sensitive point-of-care testing method, is still urgently needed to reach rapid screening of viral infections. Herein, a new lateral flow immunoassay (LFIA) platform was reported detection SARS-CoV-2 spike-S1 protein antigens, which four and specific mouse monoclonal antibodies (MmAbs) were tailored by using quantum dot (QD)-loaded dendritic mesoporous silica nanoparticles modified further achieving -COOH group surface coating (named Q/S-COOH nanospheres). Importantly, compact QD adsorption achieved channels on account highly accessible central-radial pores electrostatic interactions, leading significant signal amplification. As such, limit found be 0.03 ng/mL, lower compared with those AuNPs-LFIA (traditional colloidal gold nanoparticles, Au NPs) enzyme-linked immunosorbent assay methods. These results show that optimizing affinity antibody intensity fluorescent nanospheres simultaneously great significance improve sensitivity LFIA.

Language: Английский

---

Molecular Farming of Pembrolizumab and Nivolumab

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(12), P. 10045 - 10045

Published: June 12, 2023

Immune checkpoint inhibitors (ICIs) are a class of immunotherapy agents capable alleviating the immunosuppressive effects exerted by tumorigenic cells. The programmed cell death protein 1 (PD-1)/programmed death-ligand (PD-L1) immune is one most ubiquitous checkpoints utilized cells for evasion inducing apoptosis and inhibiting proliferation cytokine production T lymphocytes. Currently, frequently used ICIs targeting PD-1/PD-L1 include monoclonal antibodies (mAbs) pembrolizumab nivolumab that bind to PD-1 on lymphocytes inhibit interaction with PD-L1 However, costly, thus their accessibility limited in low- middle-income countries (LMICs). Therefore, it essential develop novel biomanufacturing platforms reducing cost these two therapies. Molecular farming such platform utilizing plants mAb production, has been demonstrated be rapid, low-cost, scalable can potentially implemented LMICs diminish exorbitant prices, ultimately leading significant reduction cancer-related mortalities within countries.

Language: Английский

---

Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

Pharmacology Research & Perspectives, Journal Year: 2021, Volume and Issue: 9(2)

Published: March 10, 2021

Currently, biological drug therapy for ocular angiogenesis treatment is based on the administration of anti-VEGF agents via intravitreal route. The molecules approved with this purpose use include pegaptanib, ranibizumab, and aflibercept, whereas bevacizumab commonly off-label used in clinical practice. schedule dosage involves repeated injections to achieve maintain effective concentrations retina choroids, which are administrated as solutions form. In review article, we describe features different agents, major challenges their delivery nanoparticles development system them. way, several polymeric lipid explored load aim achieving sustained release thus, minimize number required. main were focused loading that bioactivity after from nanoparticulate system, followed evaluation them through studies formulation stability, pharmacokinetic, efficacy vitro vivo models. analysis was information published peer-reviewed papers relevant treatments developed system.

Language: Английский

---